Nuvation Bio Inc. (NUVB)
NYQ · Healthcare · Biotechnology
$4.92
+3.36%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.71B
Shares Outstanding
347.2M
P/S (TTM)
11.9x
Exchange
NYQ
Currency
USD
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 4.8M | 13.1M | 41.9M | 83.2M |
| Gross Profit | 2.3M | 9.8M | 40.6M | 77.2M |
| Operating Income | -63.6M | -56.4M | -34.0M | 3.9M |
| Net Income | -59.0M | -55.8M | -36.6M | 5.4M |
| Diluted EPS | $-0.17 | $-0.16 | $-0.11 | $0.01 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.9M | 62.9M |
| Gross Profit | 0.00 | 795K | 53.6M | |
| Operating Income | -119.7M | -99.8M | -167.6M | -213.1M |
| Net Income | -104.2M | -75.8M | -567.9M | -204.6M |
| Diluted EPS | $-0.48 | $-0.35 | $-2.11 | $nan |